Core Insights - The launch of Arbli (losartan potassium) Oral Suspension, 10mg/mL, represents a significant advancement in hypertension treatment, particularly for patients with dysphagia, as it is the first FDA-approved ready-to-use liquid formulation of losartan [1][2][3] - The U.S. losartan market is valued at approximately $256 million annually, with 71 million prescriptions, indicating a substantial market opportunity for Arbli [2][3] - The availability of Arbli through established pharmaceutical distribution channels enhances treatment adherence and addresses the needs of underserved patient populations, including the elderly and children [2][3] Company Overview - Scienture Holdings, Inc. is focused on developing and commercializing novel specialty products to meet unmet market needs, with Arbli being a key product in their portfolio [1][9] - The company aims to convert regulatory milestones into market results, viewing the launch of Arbli as a driver for near-term revenue growth and a validation of their patient-focused strategy [3][9] Product Details - Arbli is a peppermint-flavored oral liquid formulation that does not require refrigeration and has a shelf life of 24 months when stored at room temperature [4] - It is indicated for the treatment of hypertension in adults and children over six years old, and it helps reduce the risk of cardiovascular events [6][8]
SCIENTURE’S Arbli™ Becomes First FDA-Approved Ready-to-Use Liquid Losartan Available Through Major U.S. Wholesalers